2128. In Vitro Activity of Ceftibuten-Avibactam and Comparator Agents Against Resistant Enterobacterales from UTIs Collected Globally as Part of the ATLAS Surveillance Program, 2022

BACKGROUND: Increasing resistance among agents commonly prescribed to treat urinary tract infections (UTIs) indicate that new orally bioavailable agents are needed. Ceftibuten (CTB) is an orally administered third-generation cephalosporin and is in early clinical development being combined with an o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hackel, Meredith, Stone, Gregory, Sahm, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679126/
http://dx.doi.org/10.1093/ofid/ofad500.1751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679126/
http://dx.doi.org/10.1093/ofid/ofad500.1751

Ejemplares similares